Relay Therapeutics will release its fourth quarter and full year 2025 financial results on February 26, 2026, providing investors with updated information on the clinical-stage biopharmaceutical company's operational progress and cash position.
The company's lead candidate, zovegalisib, a PI3Kα inhibitor, is advancing through Phase 3 clinical trials for two indications: hormone receptor-positive, HER2-negative metastatic breast cancer and PI3Kα-driven vascular anomalies. In a significant regulatory development, the drug recently secured FDA Breakthrough Therapy Designation based on clinical efficacy data, positioning it as a potential advancement in both therapeutic areas.
The February earnings call will offer stakeholders an opportunity to assess Relay's financial runway and receive updates on ongoing trial progress as the company progresses toward potential regulatory submissions.